

Bridging the Gap between Science and Clinical Practice

NIDA:

Wilson Compton, MD, MPE

Geetha Subramaniam, MD, DFAACAP, DFAPA

ASAM Science Initiative Special Interest Group:

Ken Freedman, MD, MS, MBA, FACP, AGAF, DFASAM (Chair)



Presented at the 56th ASAM Annual Conference on April 26, 2025

Disclosure Information

No Disclosures:

Geetha Subramaniam, MD, DFAACAP, DFAPA

Disclosures:

Wilson Compton, MD, MPE

☀ Stock Equity (long-term):

- ☀ 3M Company (under \$10,000)
- ☀ Pfizer, Inc. (under \$10,000)

Ken Freedman, MD, MS, MBA, FACP, AGAF, DFASAM

- ☀ Aetna, a CVS Health Company (Clinical Condition: Med/surg care): Medical Director
- ☀ The Recovery Research Network (Clinical Condition: Opioid use disorder): Medical Director


NIDA: Select Updates

Wilson M. Compton, MD, MPE


Geetha Subramaniam, MD, DLFAPA, DFAACAP

Drug Overdose Deaths: Overall Decrease

12 Month-ending Provisional Counts of Drug Overdose Deaths: United States (as of 1/5/25)




Drug Overdose Deaths Remain Elevated in Specific Populations: Highest in AI/AN NH and Black/AA NH: Final Overdose Data



CDC, NCHS. National Vital Statistics System, provisional overdose death counts and mortality 1999-2023 on CDC WONDER online database.

When separated by age and sex, overdose deaths are highest among older Black and AI/AN NH men (55+)



CDC, NCHS. National Vital Statistics System, mortality 1999-2023 on CDC WONDER online database.



Native Collective Research Effort to Enhance Wellness (N CREW)

- ☀ **N CREW** is addressing overdose, substance use & pain
- ☀ **T/NASOs** plan and develop research and/or data improvement projects.
- ☀ **Native Research Resource Network (NRRN)** will provide training, resources and program coordination.



Stimulant Use Disorder and Overdose

Early Preclinical	Late Preclinical	Clinical Trials			
		Phase I	Phase Ib	Phase II	Phase III
<u>SBI-0801315/SBI-0799220</u> <u>CocH5-Fc(M6) Cocaine hydrolase</u> <u>SBS-518</u>	<u>OMS 182399</u> <u>PPL-138</u> <u>IXT-m200 Long – Acting</u> <u>NHB 1109</u>	<u>Zolmitriptan</u> <u>TMP-301</u> <u>Cocaine hydrolase gene therapy</u> <u>dAdGNE</u> <u>h2E2</u> <u>CS-1103</u> <u>SXC-2023-Glutamate Modulator</u>	<u>Cariprazine</u> <u>Mirtazapine</u> <u>Clavulanic acid</u> <u>Ketamine</u> <u>Exenatide</u> <u>BICX104/Bupropion</u> <u>STP-7-Mavoglurant</u>	<u>Pioglitazone</u> <u>Rotigotine</u> <u>Bupropion/Naltrexone</u> <u>TNX-1300</u>	

NIDA's Clinical Trials Network



Appalachian Node

University of Pittsburgh

Big South/West Node

UT Southwestern Medical Center
University of California, Los Angeles

Clinical Coordinating Center

The Emmes Corporation

Data & Statistics Center

The Emmes Corporation

Florida Node Alliance

University of Miami
Columbia University

Great Lakes Node

University of Illinois Chicago
Research Triangle Institute
Howard University

Greater Intermountain Node

University of Utah

Greater Southern California Node

University of California, Los Angeles

Health Systems Node

Kaiser Foundation Hospitals



New England Consortium

Yale University
McLean Hospital

New York Node

New York University
Columbia University

Northeast Node

Dartmouth College

Northstar Node

Hennepin Healthcare Research Institute

Ohio Valley Node

University of Cincinnati

Pacific Northwest Node

University of Washington
Washington State University

Southwest Node

University of New Mexico
Arizona State University

Southern Consortium Node

Medical University of South Carolina

Western States Node

Oregon Health & Science University
Stanford University

Cascade Of Care: Treatment as OD Prevention

Risk Identification

CTN Study	Intervention
TAPS, S2BI	Screening tool validation
PHARMSCREEN	Pharmacy-Based narcotic
CDS	Clinical decision support
STOP	Prevention of escalation

Engagement and Linkage to MOUD

CTN Study	Intervention
PROUD	Nurse care management for OUD
SWIFT	Rapid XR-NTX initiation
EXHIT ENTRE	XR-BUP initiation Consultation service hubs for MO
HI-SIRI	Integrated SUD and infectious dis
ED-INNOVATION	XR-BUP initiation

Retention in Treatment/Recovery

CTN Study	Intervention
RDD (Retention Phase)	High dose SL-BUP
	XR-BUP
	Digital therapeutic
MOMs	XR-BUP in pregnancy
Office-Based Methadone vs. Buprenorphine	Office-based methadone

Discussion Questions

1. What are the implications of the decreasing, but still elevated rate of overdose deaths for your practice?
2. How comfortable are you in recommending use of psychedelics as part of treatment for your patients with substance use disorders? What about GLP-1 agonists?
3. What are your most pressing questions about treating co-occurring psychiatric and SUD disorders? How are you managing patients with these complex co-occurring conditions?

ASAM Science Initiative

Special Interest Group (SIG) Co-Chairs:

☀ Ken Freedman, MD, MS, MBA, FACG, AGAF, DFASAM

☀ Tami Mark, PhD, MBA

Presented at the 56th ASAM Annual Conference on April 26, 2025



Quality
Improvement
Council (QIC)

- Provide strategic oversight of ASAM's QI work
- Select ASAM representatives on QI-related initiatives
- Make recommendations to the Board regarding ASAM endorsement of QI-related materials

Science Initiative
Special Interest
Group

Clinical Guideline
& Methodology
Workgroup

ASAM Criteria
Strategy
Committee

- Promote science-related activities among ASAM membership (e.g., informal presentations, science-related sessions at ASAM Conferences)

Coalition for National
Clinical Criteria
(external advisory group)

ASAM Science Initiative Goals

- ☀️ Promote research to address current clinical challenges and drive improvements in the quality of care for addiction
- ☀️ Support ASAM members who want to become engaged in research
- ☀️ Support more rapid dissemination of research

Get Involved with the Science Initiative SIG

Join Our Community on ASAM Connect!

Contact us to learn more:

Ken Freedman, MD, MS, MBA, FACG, AGAF, DFASAM (Science Initiative SIG Chair):

☀ Email: kifreedman@verizon.net

Tami Mark, PhD, MBA (Science Initiative SIG Co-Chair; Senior Research Scientist):

☀ Email: tmark@rti.org

Anna Pagano, PhD (ASAM Senior Director of Science):

☀ Email: apagano@asam.org

<https://www.asam.org/membership/Communities>




Your Feedback Matters!

- ☀ Help inform the clinical relevance of addiction medicine research initiatives by answering this questionnaire:

QUESTIONNAIRE LINK:

<https://www.surveymonkey.com/r/BTG2025>



References

1. CDC, NCHS. National Vital Statistics System, provisional overdose death counts and mortality 1999-2023 on CDC WONDER online database.
2. CDC, NCHS. National Vital Statistics System, mortality 1999-2023 on CDC WONDER online database.